Form 4: Revolution Medicines COO Sells Shares for Tax Obligations

Revolution Medicines' Chief Operating Officer, Margaret Horn, sold 4,775 shares of common stock to cover tax obligations from RSU vesting.

Summary

• Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• The transaction involved 4,775 shares of common stock.
• The shares were sold at a price of $45.8249 per share.
• The sale occurred on September 16, 2025.
• This transaction was executed pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023.
• The purpose of the sale was to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs).
• Following this transaction, Ms. Horn beneficially owns 145,900 shares of common stock, which includes 70,500 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine, pre-planned insider stock sale for tax purposes, which is a neutral event and does not reflect positively or negatively on the company's operational or financial performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine event for publicly traded companies, typically not indicative of broader industry trends or competitive shifts. It reflects an individual executive's financial planning rather than a company-wide strategic move.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, pre-planned sale for tax purposes and not a discretionary sale signaling a change in management's outlook on the company's prospects.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider stock sale by the Chief Operating Officer to cover tax obligations from RSU vesting. Such transactions, executed under a Rule 10b5-1 plan, are generally not considered indicative of management's sentiment towards the company's future performance and do not alter the fundamental investment thesis. Therefore, a 'hold' recommendation is appropriate as this event does not provide new information to warrant a change in investment strategy.

Keywords

RVMD, Revolution Medicines, Form 4, Insider Transaction, Stock Sale, Margaret Horn, Chief Operating Officer, 10b5-1 Plan, Restricted Stock Units, Tax Withholding